Stockwatch: A Week Of Dashed Expectations

Last week was another losing week in broad stock markets, driven by fears of a Brexit. The S&P 500 index was depressed by about 1% and in what is becoming an unwelcome recent trend, the NASDAQ Biotech index (NBI) underperformed the broad stock market by finishing the week down over 4%. While some of this underperformance can be attributed to risk-aversion at a time of short-term macroeconomic uncertainty, missed expectations in life science companies did not help matters.

stock

Having come a long way (down) since the peak of last summer, investors are interested in when life science stocks will stabilize, and then when they will start to outperform broad stock markets again. Technical analysts or chartists look at share price graphs and pronounce some meaning from the patterns. However, I tend think of technical analysts in the same way as Robert Harris’ character Cicero (in his historical fiction series on ancient Rome) thought of the auguries and soothsayers of the day. To bring Cicero’s quote up to date, no doubt birds and entrails have their place in civilian government, but they sit badly with the prediction of stock market trends.

When the sector renaissance occurs, it will be when the positive fundamental drivers of the sector – new blockbuster product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D